- Omeros Corporation (NASDAQ:OMER) has entered into a research collaboration with the University of Cambridge, establishing the Omeros Center at Cambridge for Complement and Inflammation Research (OC3IR).
- The OC3IR currently is focusing on research related to OMS721, Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), and to OMS906, a human monoclonal antibody targeting MASP-3.
- OMS721 is currently in three Phase 3 clinical programs – stem cell transplant-associated thrombotic microangiopathy, IgA nephropathy and atypical hemolytic uremic syndrome – and OMS906 is planned to enter the clinic in early 2020. Omeros holds proprietary positions around both MASP-2 and MASP-3.